Several analysts have recently updated their ratings and price targets for Savara (NASDAQ: SVRA):
- 10/15/2026 – Savara had its “sell (d-)” rating reaffirmed by Weiss Ratings.
- 10/7/2026 – Savara was given a new $10.00 price target by Royal Bank Of Canada.
- 10/7/2026 – Savara had its “market outperform” rating reaffirmed by Citigroup.
- 10/7/2026 – Savara is now covered by JPMorgan Chase & Co.. They set an “overweight” rating and a $12.00 price target on the stock.
- 10/4/2026 – Savara was downgraded by Wall Street Zen from “hold” to “sell”.
- 9/26/2026 – Savara was upgraded by Wall Street Zen from “sell” to “hold”.
Savara Inc is a clinical-stage biopharmaceutical company focused on developing therapies for rare respiratory diseases. The company’s work is centered on conditions with significant unmet medical needs, particularly diseases involving impaired lung function and abnormal accumulation of material in the lungs.
Savara’s lead product candidate is molgramostim, an inhaled formulation of recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF). The therapy is being developed for autoimmune pulmonary alveolar proteinosis, a rare lung disorder in which surfactant accumulates in the airspaces and interferes with breathing.
Read More
- Five stocks we like better than Savara
- Broadcom’s AI Chip Business Is Booming, But Alphabet’s Strategy Highlights 2 Key Risks
- Amazon’s $350 Price Target Faces a Big Earnings Test
- Newmont’s Record Quarter Shows Why Gold’s Floor Is the Real Story
- Albemarle Upgrade: Can Energy Storage Recharge Lithium’s Leader?
Receive News & Ratings for Savara Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Savara Inc and related companies with MarketBeat.com's FREE daily email newsletter.
